CareTria Launches RYALTRIS® Direct to Simplify Patient Access
News related to:CareTria · 2 min read
CareTria, a leading provider of patient access and commercialization solutions, has launched RYALTRIS® Direct, a new program designed to simplify access to the nasal spray RYALTRIS® for healthcare providers and patients. This initiative combines the fulfillment capabilities of Eagle Pharmacy, LLC, with CareTria’s engagement, telesales, and sampling services.
RYALTRIS® Direct is a comprehensive program that aims to streamline the process from product sampling to prescription fulfillment. Through this offering, healthcare providers can access product samples more easily, which can help in initiating therapy for patients with seasonal allergic rhinitis. The program is particularly beneficial for providers who need to manage the complexities of patient access and therapy initiation.
CareTria’s telesales team will play a crucial role in supporting provider outreach and education. They will manage a comprehensive sampling program, including HCP-initiated requests, e-sampling, and physician-administered distribution. This coordinated effort is expected to reduce administrative complexity and accelerate the initiation of therapy for patients.
Marc Kikuchi, President & Business Head, North America at Glenmark Pharmaceuticals, emphasized the importance of this initiative.
RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg, is indicated for the treatment of symptoms associated with seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older. The new program is designed to make RYALTRIS® more accessible to patients, ensuring they can receive the treatment they need.
Patients with existing RYALTRIS® prescriptions can request that their prescriptions be transferred to Eagle Pharmacy, the dispensing pharmacy for RYALTRIS® Direct, Powered by CareTria. This transfer process is designed to be seamless, ensuring that patients continue to receive their medication without disruption.
The launch of RYALTRIS® Direct is part of Glenmark Pharmaceuticals' broader strategy to improve patient access to innovative respiratory therapies. By integrating various services into a single, coordinated program, CareTria and Glenmark aim to enhance the overall experience for both healthcare providers and patients.
In conclusion, RYALTRIS® Direct is a significant step in simplifying the access to RYALTRIS® for patients with seasonal allergic rhinitis. Through the combined efforts of CareTria and Eagle Pharmacy, the program is expected to streamline the process, reduce administrative complexity, and improve the treatment experience for patients.